We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01285752
First Posted: January 28, 2011
Last Update Posted: July 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Asahi Kasei Pharma Corporation
January 27, 2011
January 28, 2011
July 25, 2016
February 2011
January 2012   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01285752 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
Not Provided
To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: AK106-001616
  • Drug: Active comparator
  • Experimental: 1
    Intervention: Drug: AK106-001616
  • Experimental: 2
    Intervention: Drug: AK106-001616
  • Active Comparator: 3
    Intervention: Drug: Active comparator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
240
December 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of RA (class I to III)
  • Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Abnormal screening laboratory test values considered to be clinically significant
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Germany,   Hungary,   Poland,   Slovakia,   Ukraine,   United Kingdom
 
 
NCT01285752
AK106 II-02
Not Provided
Not Provided
Not Provided
Asahi Kasei Pharma Corporation
Asahi Kasei Pharma Corporation
Not Provided
Not Provided
Asahi Kasei Pharma Corporation
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP